What does OROPHARMA do?

OROPHARMA is registered with the CBE as active in: Vervaardiging van geneesmiddelen. Public Limited, started on 27 May 1987, 1 establishment.

What is the address of OROPHARMA?

The registered office of OROPHARMA is located at Kapellestraat 70, 9800 Deinze.

Is OROPHARMA still active?

Yes. According to the CBE (29 October 2026) OROPHARMA is active, legal situation “Normale toestand”, started on 27 May 1987.

Is OROPHARMA registered on Peppol?

Yes, OROPHARMA is registered on the Peppol network with ID 0208:0431268730.

What is the enterprise number of OROPHARMA?

The enterprise number of OROPHARMA is BE0431268730.

When was OROPHARMA founded?

OROPHARMA was founded on 27 May 1987.

Who are the directors of OROPHARMA?

According to the 2025 annual accounts, the directors of OROPHARMA are: Versele-Laga NV, Stefan Versele, Francis D'Hoore, Gwijde Versele.

Is OROPHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 27 May 1987; 5 annual accounts filed, latest fiscal year 2025; 4 directors known from the annual account.

How much profit did OROPHARMA make in 2025?

OROPHARMA posted a profit after taxes of € 19,264 in financial year 2025.

What is the revenue of OROPHARMA?

As a small company, OROPHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 20,797.

OROPHARMA (Public Limited) - Deinze - BE0431268730

Dossier OROPHARMA, printed on 29 October 2026 from databakkes.be/en/0431268730/oropharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Busy address KBO

29 other companies have their registered office at the same address; threshold 10.

Financials

Financial year 2025

OROPHARMA from Deinze, company number BE0431268730, closed financial year 2025 with a result of € 19,264 after tax. For that financial year OROPHARMA recorded a gross margin of € 20,797 and equity of € 197,410. Compared with financial year 2024, the result moved from € 50,929 to € 19,264. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 14, 2026.

What it is worth Growing

€ 197,410

▲ 11% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 19,264

▼ 62% vs 2024

Profit after tax over the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 135,410.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 155,027

▼ 42% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ -63,785 Gross margin 2022: € -63,785 First fiscal year in the series	€ -100,726 Gross margin 2023: € -100,726 ▼ € 36,941 vs 2022 (€ -63,785) Unfavourable step	€ 50,719 Gross margin 2024: € 50,719 ▲ € 151,445 vs 2023 (€ -100,726) Favourable step	€ 20,797 Gross margin 2025: € 20,797 ▼ 59% vs 2024 (€ 50,719) Unfavourable step	▼ 59%
Profit after taxes	€ -78,724 Profit after taxes 2022: € -78,724 First fiscal year in the series	€ -124,849 Profit after taxes 2023: € -124,849 ▼ € 46,126 vs 2022 (€ -78,724) Unfavourable step	€ 50,929 Profit after taxes 2024: € 50,929 ▲ € 175,779 vs 2023 (€ -124,849) Favourable step	€ 19,264 Profit after taxes 2025: € 19,264 ▼ 62% vs 2024 (€ 50,929) Unfavourable step	▼ 62%
Equity	€ 252,066 Equity 2022: € 252,066 First fiscal year in the series	€ 127,217 Equity 2023: € 127,217 ▼ 50% vs 2022 (€ 252,066) Unfavourable step	€ 178,146 Equity 2024: € 178,146 ▲ 40% vs 2023 (€ 127,217) Favourable step	€ 197,410 Equity 2025: € 197,410 ▲ 11% vs 2024 (€ 178,146) Favourable step	▲ 11%
Total debts	€ 392,671 Total debts 2022: € 392,671 First fiscal year in the series	€ 478,943 Total debts 2023: € 478,943 ▲ 22% vs 2022 (€ 392,671) Unfavourable step	€ 394,296 Total debts 2024: € 394,296 ▼ 18% vs 2023 (€ 478,943) Favourable step	€ 155,027 Total debts 2025: € 155,027 ▼ 61% vs 2024 (€ 394,296) Favourable step	▼ 61%
Retained profit	€ 190,066 Retained profit 2022: € 190,066 First fiscal year in the series	€ 65,217 Retained profit 2023: € 65,217 ▼ 66% vs 2022 (€ 190,066) Unfavourable step	€ 116,146 Retained profit 2024: € 116,146 ▲ 78% vs 2023 (€ 65,217) Favourable step	€ 135,410 Retained profit 2025: € 135,410 ▲ 17% vs 2024 (€ 116,146) Favourable step	▲ 17%
Balance sheet total	€ 644,737 Balance sheet total 2022: € 644,737 First fiscal year in the series	€ 606,160 Balance sheet total 2023: € 606,160 ▼ 6% vs 2022 (€ 644,737) Unchanged	€ 572,443 Balance sheet total 2024: € 572,443 ▼ 6% vs 2023 (€ 606,160) Unchanged	€ 352,437 Balance sheet total 2025: € 352,437 ▼ 38% vs 2024 (€ 572,443) Unchanged	▼ 38%

Key figures of OROPHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to OROPHARMA?

What happened at OROPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2029 Versele-Laga NV stepped down as director. NBB
2029 Stefan Versele stepped down as director. NBB
2029 Francis D'Hoore stepped down as director. NBB
2029 Gwijde Versele stepped down as director. NBB
Jul 14, 2026 New annual accounts for financial year 2025: profit of € 19,264 (▼ 62% vs 2024). Source: NBB ↗
2023 Francis D'Hoore became a director. NBB
2023 Versele-Laga NV became a director. NBB
2023 Stefan Versele became a director. NBB

In short

From € 78,724 loss in 2022 to € 19,264 profit in 2025.

Paid € 31 in corporate taxes since 2022.

Best year ever: 2024, with € 50,929 profit.

Original PDFs at the National Bank ↗

Management

Versele-Laga 99.9%

The stake of Versele-Laga comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

OROPHARMA

The shares are held by Versele-Laga (99.9%).

Directors

According to the 2025 annual accounts

Versele-Laga NV

Director · represented by Lode Versele

Also active at: GS1 Belgium & Luxembourg, ORLUX

since 2023 · until 2029

Stefan Versele

Director

Also active at: Verlatrans, HELUCA, MOLENS MARIMAN, Duvaco, BOSMOLEN, FINVOL PSI, VERLABREED, R.P.S. +27 more

since 2023 · until 2029

Francis D'Hoore

Director

Also active at: Belgian Feed Association, Versele-Laga, ORLUX, BK

since 2023 · until 2029

Gwijde Versele

Director

Also active at: Verlatrans, HELUCA, MOLENS MARIMAN, Volys Star, Duvaco, BOSMOLEN, FINVOL PSI, VERLABREED +28 more

since 2023 · until 2029

Shareholders

Versele-Laga

99.9%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Kapellestraat 70

9800 Deinze

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 29 companies are registered at this address.

All companies at this address →

Verlatrans same network

€ 469,688 gross margin · 2025

HELUCA same network

€ 4.4 million revenue · 2025

MOLENS MARIMAN same network

€ 41,762 gross margin · 2025

Duvaco same network

€ -88 gross margin · 2025

BOSMOLEN same network

€ 280,772 gross margin · 2025

+24 more

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0431.268.730

VAT number

BE 0431.268.730

Registered office

Kapellestraat 70, 9800 Deinze

Names & denominations

OROPHARMA

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

27 May 1987

Peppol

Active · Active since 1 Jan 2001

Activities · NACE

Vervaardiging van geneesmiddelen

Groothandel in farmaceutische en medische artikelen

Groothandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗

OROPHARMA

Warning lights

Financials

What happened to OROPHARMA?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions